Shots:
The US FDA has accepted an NDA for bezuclastinib in pts with AdvSM, plus set a PDUFA target action date of Jun 29, 2027, with no plans to hold an advisory committee, as well as no potential review issues identified
NDA was backed by the APEX trial, which showed as of Mar 31, 2026,…
